WO2007074916A1 - 3,4-ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 - Google Patents
3,4-ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 Download PDFInfo
- Publication number
- WO2007074916A1 WO2007074916A1 PCT/JP2006/326314 JP2006326314W WO2007074916A1 WO 2007074916 A1 WO2007074916 A1 WO 2007074916A1 JP 2006326314 W JP2006326314 W JP 2006326314W WO 2007074916 A1 WO2007074916 A1 WO 2007074916A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- neuralgia
- group
- chronic
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a novel 3,4-dihydrobenoxoxazine compound having vanilloid receptor type 1 (VR1) activity inhibitory action and a pharmaceutically acceptable salt thereof, the compound or a pharmaceutically acceptable salt thereof.
- Pharmaceutical compositions containing salt as an active ingredient Pain, Acute pain, Chronic pain, Neuropathic pain, Rheumatoid arthritis pain, Neuralgia, etc. Diseases involving vanilloid receptor type 1 (VR 1) activity, especially pain It relates to therapeutic methods and Z or preventive methods.
- VR1 vanilloid receptor type 1
- Capsaicin the main component of pepper, is both a hot ingredient and a pain killer.
- Many nociceptive nerves, especially unmyelinated C fibers, have been reported to be sensitive to cabsaicin, and it has been shown that administration of kabusaicin to early-stage rodents causes selective loss of C fibers. Yes.
- the site of action of kabusaicin is distributed widely in the skin, cornea, and oral mucosa, and distribution is also observed in muscles, joints, internal organs, especially in the cardiovascular system, respiratory system, and bladder urinary system. It is also reported that it is important.
- Capsaicin sensitivity has also been observed in nerves in the preoptic area of the thalamus, and it has been speculated that it is involved in thermoregulation.
- nociceptive nerves depolarization due to influx of Na + and Ca 2+ was observed when capsaicin was administered, and glutamate and neuropeptides (mainly substance P from the central ending of the primary afferent fiber in the dorsal horn of the spinal cord) were observed. And calcitonin gene-related peptide).
- the specific binding activity of resiniferatoxin (RTX) which has the same effect as cabsaicin, and the ability of capsazepine as a competitive inhibitor have been revealed.
- Non-patent Document 1 kabusaicin acts on a receptor protein
- the capsaicin receptor gene was cloned (see, for example, Cater ina MJ, Schumacher MA'onunaga, Posen TA, Levine JD, Julius D. (1997) Nature 389, 816-824 (Non-patent Document 2)).
- From the amino acid sequence it was estimated that it would be an ion channel with six transmembrane domains.
- VRl was found to be a non-selective cation ion channel with outward rectification and high Ca 2+ permeability (eg, Premkumar LS, Agarwal S, Steffen D. (2002) J. Physiol .. 545, 107-117 (see Non-Patent Document 3);).
- Kabusaicin is a substance that causes pain, but it is used as an analgesic to reduce pain in diabetic and rheumatic neuropathies (for example, Szallasi A, Blumberg P. (1999)). Pharmacol. Rev. 51, 159-212 (Non-Patent Document 1)). This is understood to be due to the desensitization that sensory nerve endings exposed to kabusaicin fail to respond to painful stimuli. The desensitization mechanism of VR1 is thought to involve regulation via, regulation depending on potential, and regulation of VR1 activity by phosphorylation / dephosphorylation, but there are still many unclear points.
- Patent Document 5 It can be seen that acidification (proton) alone can directly activate VR1 by reducing extracellular pH within the range of acidification caused by tissue damage. VR1 is due to tissue acidification that occurs during inflammation ischemia. It is presumed to be the molecular reality of stimulus reception (see, for example, Yang D, Gereau RW 4th. (2002) J. Neurosci. 22, 6388-6393 (Non-Patent Document 4)).
- Inflammatory substances extracellular ATP, bradykinin, and neuro growth factor have also been reported to increase VR1 activity (eg Tominaga M, Wada M, asu M. (2001) Pro Natl. Acad. Sci USA 98, 6951-6956 (Non-Patent Document 8), Shu X, Mendell LM. (1999) Neurosci. Lett. 274, 159-162 (Non-Patent Document 9), Chuang HH, Prescott ED, Kong H, Shields S , Jordt SE, Basbaum AI, Chao, MV, Julius D.
- Non-Patent Document 12 (2001) Nature 411, 957-962 (Non-Patent Document 10) and Sugiura T, Tominaga ⁇ , Katsuya ⁇ , izuraura ⁇ . (2002) J. Neurophysiol. 88, 544-548 (Non-Patent Document 1 1)), and it is said that VR1 is involved in inflammation and other pain and hyperalgesia (for example, Numazaki M, Tominaga). M (2003) Biochemistry 75, 359-371 (see Non-Patent Document 12).)
- VR1-deficient mice did not respond to capsaicin, proton, or heat. In behavioral analysis, it has also been reported that VR1-deficient mice do not show a pain response due to the administration of kabusaicin, and the sensitivity to thermal stimulation is reduced, and inflammatory hyperalgesia is not observed (eg, Caterina MJ, Leffler A , almberg AB, Martin WJ, Trafton J, Peterson-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D. (2000) Science 288, 306-313 (1 3) and Davis LB, Gray J, Gunthorpe MJ et al. (2000) Nature 405, 183— See 187 (Non-Patent Document 14). ) In this way, analysis of VR1-deficient mice has confirmed that VR1 functions as a wide range of pain stimulus receptors even at the individual level.
- VR 1 vanilloid receptor type 1
- capsazepine a known VR1 antagonist
- analgesic effects in animal models (eg, Ikeda Y, Ueno A, Naraba H, Oh-ishi S, ( 200l) Life Science 69, 2911-2919 (see Emergency Patent Document 15)), and it is highly expected to be used as a new therapeutic agent for pain with VR1 activity inhibitory action.
- a substance having antagonistic activity of vanilloid receptor type 1 prevents and treats diseases associated with VR 1 activity, In particular urge incontinence, bladder overactivity, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritis pain, neuralgia, neuropathy, hyperalgesia, nerve damage, ischemia, neurodegeneration, stroke, incontinence, and It has also been reported that it is useful for the prevention and treatment of inflammatory diseases (see, for example, Japanese Patent Application Laid-Open No. 2000-0319 2 673 (Patent Document 1)).
- Diseases associated with vanilloid receptor activity include pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, joint pain, neuropathy, nerve damage, diabetic neuropathy, Neurodegenerative diseases, neurological skin diseases, stroke, bladder hypersensitivity, irritable bowel syndrome, respiratory abnormalities such as asthma and chronic obstructive pulmonary disease, irritation of skin, eyes, or mucous membranes, fever, stomach-duodenal ulcer The inflammation It is also known that inflammatory bowel diseases, inflammatory diseases, and the like can be included (see, for example, Japanese Patent Application Publication No. 2000-504 (see Patent Document 2)).
- a substance having antagonistic activity of vanilloid receptor type 1 is a pathological condition involving C fibers, such as pruritus, allergic and allergic rhinitis, bladder overactive type Urinary incontinence, urinary incontinence, stroke, irritable bowel syndrome, asthma, respiratory diseases such as chronic obstructive pulmonary disease, dermatitis, mucositis, stomach / duodenal ulcer, inflammatory bowel syndrome, Pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, joint pain, neuropathy, nerve damage, diabetic neuropathy, neurodegenerative disease, rheumatoid arthritis pain, neuralgia, neuropathy, pain sensation It can be said that it is useful as a therapeutic agent for hypersensitivity, neurological skin disease, stroke, obesity, urge incontinence, ischemia, inflammatory disease, and the like.
- a known vanilloid receptor type 1 (VR 1) antagonist and a compound that is considered to be relatively close to the compound of the present invention will be
- WO 0 3/0 6 8 7 4 9 describes amide compounds represented by the following general formulas [A], [B], and [C] as compounds exhibiting an antagonistic action against VR1. Things are listed. (See Patent Document 3.)
- WO 0 3/0 8 0 5 7 8 describes a urea compound represented by the following general formula [D] as a compound having an antagonistic action against VR1 (Patent Document) See 4.)
- WO 0 3/0 0 6 0 1 9 describes a compound having an inhibitory effect on force saicin-induced plasma protein extravasation in the urinary bladder. Lou 1, 2, 3, 4—Tetrahydrodroisoquinoline-2-carboxylate is described (see Patent Document 5).
- WO 0 3 0 5 3 9 4 5 describes a urea compound represented by the following general formula [E] as a compound exhibiting an antagonistic action against VR1 (see Patent Document 6) )
- WO 0 3/0 9 9 2 8 4 describes a compound represented by the following general formula [F] as a compound showing binding activity to VR 1 (Patent Literature) Refer to 7.) [F]
- Non-Patent Document 1 Szallasi A, Blumberg PM. (1999) Pharmacol. Rev. 51, 159-212
- Non-Patent Document 2 Cater ina MJ, Schumacher MA Tominaga M, Posen TA, Levine JD, Julius D. (1997) Nature 389, 816-824
- Non-Patent Document 3 Premkumar LS, Agarwal S, Steffen D. (2002) J.
- Non-Patent Document 4 Yang D, Gereau RW 4th. (2002) J. Neurosci. 22,
- Non-Patent Document 6 Carlton SM, Coggeshall RE. (2001) Neurosci. Lett.
- Non-Patent Document 7 Yiangou Y, Facer P, Dyer NH, Chan CI, Knowles C, Williams NS, Anand P. (2001) Lancet 357, 1338-1339
- Non-Patent Document 8 Tominaga M, Wada, Masu M. (2001) Proc. Natl. Acad.
- Non-Patent Document 9 Shu X, Mendell LM. (1999) Neurosci. Lett. 274, 159-162
- Non-Patent Document 1 Chuang HH, Prescott ED, Kong H, Shields S, Jordt
- Non-Patent Literature 1 1 Sugiura T, Tominaga, Katsuya H, izumura K.-(2002) J. Neurophysiol. 88, 544 -548
- Non-patent literature 1 2 Numazaki M, Tominaga M (2003) Biochemistry 75, 359-371
- Non-patent literature 1 3 Caterina J, Leffler A, almberg AB, Martin WJ,
- Non-Patent Document 1 4 Davis LB, Gray J, Gunthorpe MJ et al. (2000) Nature
- Non-Patent Document 1 Ikeda Y, Ueno A, Naraba H, Oh-hishi S, (2001) Life
- Non-Patent Document 1 6 (2002) Nat. Neurosci. 5, 856-860
- Patent Document 1 Japanese Patent Laid-Open No. 2 0 0 3 ⁇ 1 9 2 6 7 3
- Patent Document 2 Special Table 2 0 0 4 ⁇ 5 0 6 7 1 4
- Patent Document 3 WO O 3/0 6 8 7 4 9
- Patent Document 4 wo 0 3/0 8 0 5 7 8
- Patent Document 5 woo 3/0 0 6 0 1 9
- Patent Document 6 woo 3/0 5 3 9 4 5
- Patent Document 7 woo 3/0 9 9 2 8 4
- Patent Document 8 PCT / JP 2 0 0 5/0 1 3 4 4 Disclosure of the Invention
- narcotic analgesics such as morphine
- non-narcotic analgesics NSAID (nonsteroidal anti-inflammatory drug)
- NSAID nonsteroidal anti-inflammatory drug
- neuropathic pain neuropathic pain
- diabetic neuropathic pain postherpetic neuralgia
- trigeminal neuralgia The development of analgesics is also expected.
- cabsaicin-like compounds that act on VR1 exhibit an analgesic effect based on a medicinal mechanism that is completely different from existing analgesics (blocks of cabsaicin-sensitive nerves), and neuropathic in which existing analgesics do not respond. It is highly expected to be effective as a therapeutic agent for pain caused by various pathological conditions such as pain and rheumatoid arthritis.
- VR1 is the ultimate target of various inflammation-related substances indicates that drugs that act on VR1 may be effective for various inflammatory pains and interstitial cystitis. It is highly expected to be an effective analgesic alternative.
- an object of the present invention is to provide a new analgesic, that is, a VR 1 activity inhibitor, based on a medicinal mechanism completely different from existing analgesics (capsaicin-sensitive nerve block). Is to provide.
- an object of the present invention is to provide a VR 1 activity inhibitor having not only VR 1 inhibitory activity but also excellent absorbency and sustainability and high possibility of practical use.
- Another purpose is to treat pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia and other diseases involving vanilloid receptor type 1 (VR 1) activity, particularly pain treatment methods and Or providing a preventive method.
- VR 1 vanilloid receptor type 1
- the present inventors have conducted earnest research to develop a pain relieving agent based on a new action mechanism that replaces a conventional pain relieving agent such as a non-narcotic analgesic agent, a pyriline analgesic agent, a non-pyrenic analgesic agent, and NSAIDs.
- a conventional pain relieving agent such as a non-narcotic analgesic agent, a pyriline analgesic agent, a non-pyrenic analgesic agent, and NSAIDs.
- a conventional pain relieving agent such as a non-narcotic analgesic agent, a pyriline analgesic agent, a non-pyrenic analgesic agent, and NSAIDs.
- R 2 is a C 1 16 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from the following group;
- R 3 is a halogen atom (provided that when X is CR 3 , R 1 is a nitrogen atom). ]
- a pharmaceutical composition comprising the 3,4-dihydrobenzoxazine compound or the pharmaceutically acceptable salt thereof according to 1 or 2 above and a pharmaceutically acceptable carrier.
- Pain, acute pain, chronic pain, nerve comprising the 3,4-dihydrobenzoxazine compound or the pharmaceutically acceptable salt thereof described in 1 or 2 above and a pharmaceutically acceptable carrier. Painful pain, rheumatoid arthritis, neuralgia, neuropathy, hyperalgesia, migraine, joint pain, acute postherpetic neuralgia, postherpetic neuralgia, chronic postherpetic neuralgia, postoperative neuralgia, cancerous Pain, inflammatory pain, interstitial cystitis, post-traumatic neuralgia, glycouria neuropathy, neurodegeneration, stroke, ischemia, nerve injury, neurological skin disease, inflammatory disease, pruritus , Allergic rhinitis, stroke, irritable bowel syndrome, asthma, chronic obstructive pulmonary disease, dermatitis, mucositis, stomach, duodenal ulcer, inflammatory bowel syndrome, bladder hypersensitivity, frequent urination, and urinary incontinence Disease treatment and / or The pharmaceutical composition for anti
- Treatment or Z or prevention of pain comprising the 3,4-dihydrobenzoxazine compound or the pharmaceutically acceptable salt thereof described in 1 or 2 above and a pharmaceutically acceptable carrier.
- Pain Acute pain, Chronic pain, Neuropathic pain, Rheumatoid arthritis Pain, Neuralgia, Neuropathy, Hyperalgesia, Migraine, Arthralgia, Acute postherpetic neuralgia, Postherpetic neuralgia, 6.
- the pharmaceutical composition according to 5 above which is chronic postherpetic neuralgia, postoperative neuralgia, cancer pain, inflammatory pain, interstitial cystitis, posttraumatic neuralgia, diabetic neuropathy, or neurodegeneration.
- a vanilloid receptor type 1 comprising the 3,4-dihydrobenzoxazine compound or pharmaceutically acceptable salt thereof described in 1 or 2 above and a pharmaceutically acceptable carrier.
- a method for treating pain and Z or prevention characterized by administering a pharmaceutically effective amount of the 3,4-dihydrobenzoxazine compound or a pharmaceutically acceptable salt thereof according to 1 or 2 above. Method.
- Pain is acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, neuropathy, hyperalgesia, migraine, arthralgia, acute postherpetic neuralgia, postherpetic neuralgia, The treatment method according to 9 above, which is chronic postherpetic neuralgia, postoperative neuralgia, cancer pain, inflammatory pain, interstitial cystitis, posttraumatic neuralgia, diabetic neuropathy, or neurodegeneration Prevention method.
- Pain is pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, neuropathy, hyperalgesia, migraine, arthralgia, acute postherpetic neuralgia, postherpetic neuralgia, chronic Post-herpetic neuralgia, postoperative neuralgia, cancer pain, inflammatory pain, interstitial cystitis, posttraumatic neuralgia, diabetic neuropathy, or neurodegeneration
- a hydrobenzoxazine compound or a pharmaceutically acceptable salt thereof Use of a hydrobenzoxazine compound or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising the 3,4-dihydrobenzoxazine compound according to 1 or 2 above or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and an antiviral agent.
- a pharmaceutical comprising a combination of one or more drugs selected from the group consisting of a drug, a calcium channel antagonist, a force rheum channel opener, and an antipyretic.
- 1 8. Administration of 3, 4-dihydrobenzoxazine compound or a pharmaceutically acceptable salt thereof according to 1 or 2 above, acupuncture, transcutaneous electrical acupuncture therapy, transcutaneous electrical nerve stimulation therapy , Sil ver sp i ke po i nt (SSP) therapy, terminal neural stimulation therapy, spinal cord stimulation therapy, electroconvulsive therapy, laser therapy and
- a method for treating and / or preventing pain characterized by using in combination with stimulant analgesia selected from low frequency therapy.
- a method for treating and / or preventing postoperative pain characterized by administering the 3,4-dihydrobenzoxazine compound or a pharmaceutically acceptable salt thereof.
- the 3,4-dihydrobenzoxazine compound of the present invention effectively inhibits the activity of vanilloid receptor type 1 (VR 1), so that pain, acute pain, chronic pain, neuropathic pain, Equine pain, neuralgia, neuropathy, hyperalgesia, migraine, joint pain, acute postherpetic neuralgia, herpes zoster postneural neuralgia, chronic postherpetic neuralgia, postoperative neuralgia, cancer pain, inflammatory pain, interstitial Cystitis, posttraumatic neuralgia, diabetic neuropathy, neurodegeneration, stroke, ischemia, nerve injury, neurodermal disease, inflammatory disease, pruritus, allergic rhinitis, stroke, irritable bowel Syndrome, asthma, chronic obstructive pulmonary disease, dermatitis, mucositis, stomach, duodenal ulcer, inflammatory bowel syndrome, bladder hypersensitivity, bladder overactivity type urination, and bladder overactivity type urinary incontinence
- VR 1 vanil
- agents for pain-related diseases such as chronic postherpetic neuralgia, postoperative neuralgia, cancer pain, inflammatory pain, interstitial cystitis, posttraumatic neuralgia, diabetic neuropathy, neurodegeneration, etc. It is effective as a preventive agent.
- an effect by a mechanism different from conventional analgesics is also expected.
- the 3,4-dihydrobenzoxoxazine compound of the present invention represented by the above general formula [1] not only has an excellent VR 1 activity inhibitory action, but is also difficult to undergo oxidative metabolism. In terms of sustainability, it has excellent properties, extremely high absorbability, and extremely high stability in Z or gastric juice. Such effects were not foreseen even by those skilled in the art.
- the novel compound of the present invention is an excellent compound that is more likely to be put to practical use as a pharmaceutical product.
- the “C 1-6 alkyl group” means a linear or branched anolalkyl group having 1 to 6 carbon atoms, preferably a “C 1 -4 alkyl group”.
- Specific examples of the “C 1_6 alkyl group” include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec_butyl group, a tert-butyl group, a pentyl group, and an isopentinole group.
- Tert-pentyl group hexyl group and the like.
- C 1-4 alkyl group means a linear or branched alkyl group having 1 to 4 carbon atoms, specifically a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group. , Isobutyl group, sec_butyl group, tert-butyl group, and the like.
- halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom or a chlorine atom, particularly preferably a fluorine atom.
- the “C 1-6 alkoxy group” is an alkoxy group whose alkyl moiety is the “C 1 16 alkyl group” defined above, specifically a methoxy group, Ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, 2-methinolevbutoxy group, neopentyloxy group, 1-ethylpropoxy group Group, hexyloxy group, 4-methylpentyloxy group, 3-methylpentyloxy group, 2-methylpentyloxy group, 1-methylpentyloxy group, 3,3-dimethylbutoxy group, 2,2-dimethylbutoxy group Groups, 1,1-dimethylbutoxy group, 1,2-dimethylbutoxy group, .1,3-dimethylbutoxy group, 2,3-dimethylbutoxy group, 2-ethylbutoxy group and the like.
- C 1-6 alkoxy group In addition to the above “C 1-6 alkoxy group”, the “C 1-6 alkoxy group optionally substituted with 1 to 5 halogen atoms” constitutes the C 1-6 alkoxy group site.
- C 1-6 alkyl is a halo substituted with 1 to 5, preferably 1 to 3, more preferably 3 identical or different halogen atoms, preferably 3 identical halogen atoms. Means an alkoxy group.
- haloalkoxy group examples include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a promomethoxy group, a chloromethoxy group, a dichloromethoxy group, a 2-chloromethoxy group, a 1,2- Dichlorodiethyl, 2, 2-Dichlorodiethyl, 2-Difluorodioxy, 2-Fluoroethoxy, 2, 2, 2-Trifluoroethoxy, 2, 2, 2_ Examples thereof include a toxi group and a 4-fluorobutoxy group.
- C 1 -6 alkoxy group optionally substituted with 1 to 5 hydroxyl groups means the C 1-6 alkoxy group site in addition to the above “C 1 16 alkoxy group”.
- C 1 16 alkyl group means an alkoxy group substituted with 1 to 5, preferably 1 to 2, more preferably 1 hydroxyl group. Specific examples of such an alkoxy group substituted with a hydroxyl group include a hydroxymethoxy group, a 2-hydroxyethoxy group, a 1-hydroxypropoxy group, a 3-hydroxypropoxy group, and a 4-hydroxyloxy group.
- R 1 is a hydrogen atom or a halogen atom.
- the halogen atom is preferably a fluorine atom or a chlorine atom, and particularly preferably a fluorine atom.
- R 1 is preferably a hydrogen atom
- R 1 is a halogen atom, particularly preferably a fluorine atom.
- R 3 and R 1 are simultaneously fluorine atoms. More specifically, it is as follows.
- R 1 is preferably
- R 2 is a C 1-6 alkoxy group which may be substituted with 1 to 5 substituents which are the same or different and are selected from a halogen atom and a hydroxyl group, preferably 1 to 3 halogen atoms or 1 Or a C 1 16 alkoxy group which may be substituted with 3 hydroxyl groups.
- C 1-6 alkoxy group may be a linear alkoxy group or a branched alkoxy group.
- C 1-6 alkoxy group is a C 2-5 alkoxy group which may be branched, and specifically includes an ethoxy group, an isopropoxy group, an isobutoxy group, a tert-butoxy group, 2, 2 — Examples thereof include a dimethyl group poxy group.
- C 1 16 alkoxy group optionally substituted with 1 to 3 halogen atoms means C 1 16 alkoxy substituted with 1 to 3 halogen atoms in addition to the above C 1 16 alkoxy group.
- An alkoxy group is meant.
- the C 1 16 alkoxy group substituted with 1 to 3 halogen atoms is the same or different 1 to 3 halogen atoms, preferably the same 1 to 3 halogen atoms, particularly preferably 1 Means a C 16 alkanoloxy group substituted with 3 or more fluorine atoms, specifically, 2, 2, 2-trifluoroethoxy group, 2, 2, 2-trichloro-ethoxy group, 2 , 2, 2-tribromo monoethoxy group, 2, 2, 2-triiodo-ethoxy group, and the like.
- C 1 16 alkenyloxy group substituted with 1 to 3 fluorine atoms is a C 2-5 alkoxy group substituted with 1 to 3 fluorine atoms, specifically, 2, 2, 2-trifluoro-ethoxy group and the like.
- C 1-16 alkoxy group optionally substituted with 1 to 3 hydroxyl groups means, in addition to the above C 1-6 alkoxy group, 1 to 3 hydroxyl groups, preferably 1 hydroxyl group substituted Means a C 1-6 alkoxy group;
- the C 16 alkoxy group substituted with 1 to 3 hydroxyl groups is preferably a C 2-5 alkoxy group substituted with 1 hydroxyl group. Examples include droxy-1-methyl-1-propoxy, 2-hydroxy_1,1-dimethyl-1-oxy, and the like.
- R 3 is a halogen atom, wherein the halogen atom is preferably a fluorine atom or a chlorine atom, and particularly preferably a fluorine atom. More preferably, R 3 and R 1 are simultaneously a fluorine atom.
- R 1 is a hydrogen atom
- R 2 is a C 1-6 alkoxy group which may be substituted with the same or different 1 to 3 halogen atoms.
- R 1 is a hydrogen atom
- R 2 is a C 1-6 alkoxy group which may be substituted with the same three halogen atoms, or a C 1-6 alkoxy substituted with one hydroxyl group.
- R ] is a hydrogen atom
- R 2 is a tert-butoxy group, an isobutoxy group, 2, 2,2-Trifluoro-ethoxy group or 2,2-dimethyl-propoxy group.
- R in the case where X is CR 3 and R, and R 1 and R 3 are the same or different and are halogen atoms, particularly preferably the same halogen atoms.
- R 3 and R 1 are simultaneously fluorine atoms.
- Preferred R 2 when X is CR 3 is an ethoxy group, isopropoxy group, isobutoxy group, .tert-butoxy group, C 2-5 alkoxy group such as 2,2-dimethylmonopropoxy group, etc .; 2 , 2, 2—Trifluoro-ethoxy group, 2, 2, 2—Trichloro mouth, 1 Etoxy group, 2, 2, 2—Trib mouth, Moethoxy group, 2, 2, 2—Trido-ethoxy group, etc.
- R 1 and R 3 are preferably the same or different and are a halogen atom, particularly preferably a fluorine atom, and R 2 is preferably a fluorine atom and a hydroxyl group A C 1-6 alkoxy group which may be substituted with the same or different substituents selected from 1 to 3, more specifically, an ethoxy group, a tert_butoxy group, an isopropoxy group, 2, 2 2, 2-trifluoro-ethoxy group, 2-hydroxy 2-methyl monopropoxy group, or 2-hydroxy 1,1-dimethyl ethoxy group.
- the “pharmaceutically acceptable salt” in the present invention may be any salt as long as it forms a salt with the compound represented by the general formula [1].
- hydrochloric acid, sulfuric acid, phosphoric acid, odor Inorganic acids such as hydrofluoric acid; or oxalic acid, malonic acid, succinic acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, darconic acid, ascorbic acid, methinolesulphonic acid, p — It can be obtained by reacting with an organic acid such as toluenesulfonic acid, benzenesulphonic acid or benzylsulfonic acid; or an amino acid such as lysine, arginine or alanine.
- hydrates or hydrates and solvates of each compound are also included.
- various isomers exist.
- E isomers and Z isomers exist as geometric isomers, and if an asymmetric carbon atom exists, enantiomers and diastereomers exist as stereoisomers based on these isomers. Mutants can exist. Accordingly, the scope of the present invention includes all these isomers and mixtures thereof.
- the present invention also includes prodrug compounds and metabolic compounds of these compounds as equivalent compounds. .
- Prodrug is a compound of the present invention that has a group that can be chemically or metabolically decomposed, and after chemical administration to a living body, is chemically changed to a compound having a pharmaceutical activity. Derivatives and non-covalent complexes and salts.
- Prodrugs are used, for example, for improved absorption in oral administration or for targeting to target sites.
- modification site for prodrug formation include highly reactive functional groups such as a hydroxyl group and an amino group in the compound of the present invention.
- Specific examples of the hydroxyl-modifying group include a acetyl group, propionyl group, isobutyryl group, bivaloyl group, benzoinole group, 4-methylbenzoinole group,: dimethinole rubamoyl group, and snorefo group.
- amino group-modifying group examples include: a hexylcarbamoyl group, a 3-methylthio-1- (propylamino) propyl group, a 1-sulfo-1- (3-ethoxy-4-hydroxyphenyl) Examples thereof include a methyl group and (5-methyl-1-2-oxo_1,3-dioxol-4-ynole) methyl group.
- the “pharmaceutical composition” includes, in addition to the so-called “composition” composed of an active ingredient and a compounding agent as a medicine, a combination with other drugs and the like.
- this pharmaceutical composition may be used in combination with any other drug within a range that is acceptable in the medical field. Therefore, it can be said that this pharmaceutical composition is a pharmaceutical composition for use in combination with other drugs.
- “Pain” is used regardless of the symptom (eg, dull or acute pain, chronic or acute), and regardless of the type of disease that causes the pain (eg, It can be any pain symptom, whether it is a pain caused by rheumatism or a pain caused by cancer.
- pain here refers to what is called “pain”, as well as acute pain, chronic pain, Painful pain, rheumatoid arthritis pain, neuralgia, neuropathy, hyperalgesia, migraine, arthralgia, acute postherpetic neuralgia, postherpetic neuralgia, chronic postherpetic neuralgia, postoperative neuralgia, cancer It includes sexual pain, inflammatory pain, interstitial cystitis, posttraumatic neuralgia, diabetic neuropathy, and neurodegeneration.
- the “vanilloid receptor type 1 (VR 1) activity inhibitor” refers to a substance that inhibits the function of the vanilloid receptor type 1 as an ion channel and loses or attenuates its activity. Specific examples include vanilloid receptor type 1 antagonist.
- the vanilloid receptor type 1 antagonist is a substance that inhibits the effect of the agonist acting on the vanilloid receptor type 1 and inhibits the function of the vanilloid receptor type 1 as an ion channel. Say. Further, the inhibitor may inhibit the function as a VR 1 ion channel without competing with the agonist.
- agonists acting on vanilloid receptor type 1 include kabusaicin, kabusaicin derivatives, acid stimulation (proton), thermal stimulation, etc., but vanilloid receptor type 1 (VR 1)
- the activity inhibitor may be a substance that inhibits intracellular Ca 2+ influx by cabsaicin, acid stimulation (proton), or acupuncture stimulation.
- the pharmaceutical composition of the present invention is not limited to humans, but other mammals (mouse, rat, hamster, usagi, cat, inu, ushi, horse, hedge, monkey, etc.) Can be administered. Therefore, the pharmaceutical composition of the present invention is useful not only for humans but also for veterinary drugs.
- the compound of the present invention When used as a pharmaceutical preparation, it is usually a known pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, buffer, emulsifier, aroma.
- oral Wakashi Ku can be administered parenterally.
- the dose varies depending on age, weight, symptoms, therapeutic effects, administration method, etc., but is usually in the range of 0.1 mg to 1 g per adult, once to several times a day. It is administered in the form of an injection such as an oral preparation or intravenous injection.
- prevention is so-called prevention, and refers to, for example, preventing the onset of neuralgia or chronicity of neuralgia prophylactically.
- pain specifically, the development of acute postherpetic neuralgia, the development of postherpetic neuralgia, the transition from acute herpes zoster pain to postherpetic neuralgia, the chronicity of postherpetic neuralgia, the development of postoperative neuralgia Chronic postoperative neuralgia, onset of cancer pain, onset of cancer pain, onset of inflammatory pain, onset of interstitial cystitis, chronicity of inflammatory pain, onset or trauma of posttraumatic neuralgia Prophylactic suppression of chronic neuralgia and the like can be mentioned.
- “Pharmaceutical comprising a combination” refers to a pharmaceutical composition comprising the compound of the present invention [1] or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition or a combination containing the pharmaceutical composition to be combined with these compositions. It is a kit comprising a pharmaceutical composition characterized by being, a pharmaceutical composition comprising the compound of the present invention [1] or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition or drug combined with these compositions, And a pharmaceutical composition comprising the compound of the present invention [1] or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition or drug combined with these compositions, each administered by the same or different route of administration. Means a pharmaceutical or the like characterized by
- the compound or pharmaceutical composition of the present invention can be used in combination with one or a plurality of other drugs by a general method performed in a normal medical field.
- the drugs to be used in combination may be administered simultaneously, or may be administered separately with a time lag.
- antiviral agents antidepressants, anticonvulsants, antiarrhythmic agents, local anesthetics, anesthetics, N-methyl-D-aspartate receptors Antagonist, corticosteroid, nerve block, non-steroidal anti-inflammatory analgesic, narcotic, antagonistic analgesic, 2adrenergic receptor agonist, stimulant analgesic, topical, calcium channel antagonist, potash Um channel openers and antipyretics are preferred.
- antiviral agent examples include vidarabine, acyclovir, gancik mouth building, zidovudine, didanosine, amantadine, idoxuridine, and interferon.
- antidepressants include: amitriptin, imipramine, clomipramine, trimipramine, oral fuepramine, doslevin, desipramine, amoxapine, nortriptyline, fluoxetine, fluvoxamine, maprotiline, metheptiline, Examples include trazodone.
- anticonvulsants include gabapentin, pregapariline, phenobarbital, primidone, phenytonin, mephenytonin, dirubanol, ethtoin, trimetadione, ethosuccimide, and acetylylphene. Tolydo, carbamazepine, zonisamide, acetazolamide, diazepam, cloronazebum, diazepamazem, diphenylhydantoin, valproic acid, baclofen, and the like.
- antiarrhythmic drugs include quinidine, disoviramide, pro-forced amide, azimarin, prazimarium, cybenzoline, lidocaine, lidocaine, mexiletine, caprindin, tonicide, phenytoin, flecainide.
- local anesthetics include lidocaine, mexiletine, force-in, pro-in, bupiva-in, mepiva-in, prelocaine, tetrakine, jib Force in, ethyl benzoate and the like.
- anesthetics include benzodiazepine, diazepam, midazolam, thiopentanole, thiamiranole, provoforenole, kurofen, dolphin mouth nore, and swentinole. It is done.
- N-methy l-D-aspartate receptor antagonists include ketamine, dextromethorphan, memantine, and amantadine.
- corticosteroids include cortisol, cortisone, prednisolone, triamcinolone, dexamethasone, betamethasone, noramethasone, fluocinolone acetonide, fluocinonide, vector methasone, flucortisone, Etc.
- Nerve blocks include stellate ganglion block, epidural block, arm plexus block, nerve root block, chest / lumbar sympathetic ganglion block, ⁇ rigger point block, subarachnoid block, trigeminal nerve block Sympathetic nerve block, local infiltration block, peripheral nerve block, and the like.
- non-steroidal anti-inflammatory analgesics include celecoxib, oral fuecoxib, etodolac, meloxicam, nimesulide, diclofenac sodium, mefenamic acid, monkey ⁇ profen, loxoprofenato Lithium, sulindac, nabumetone, diflunisal, piroxicam, ibuprofen, naproxen, phenoprofen, acetylsalicylic acid, tolmethine, indomethacin, flurbiprofen, oxaprozin, ketobuchifen, mofezolac, acetoamino Examples include phen, ketorolac, zomepirac, nitroaspirin, thiaprofen, ampiroxicam, thiaramide, and epilizole.
- drugs include morphine, fentanyl, oxycodone, methadone, codin, cocaine, pethidine, opium and tocon.
- antagonistic analgesic examples include pentadine, buprenorphine, nalorfine, cyclazosin, butofanol.
- ct2-adrenergic receptor agonists include clonidine, dexmedetomidine, tizanidine, guanfacine, and guanabens.
- topical drugs include turnip sincreme.
- antipyretic examples include diclofenac sodium, mefenamic acid, loxoprofen sodium, ibuprofen, acetyl salicylic acid, indomethacin, and acetoaminophen.
- stimulation and analgesia include acupuncture, percutaneous electrical acupuncture, transcutaneous electrical nerve stimulation, sil ver sp i ke po i nt (SSP) therapy, peripheral nerve stimulation, Examples include spinal cord electrical stimulation, electroconvulsive therapy, laser therapy, and low frequency therapy.
- the compound of the present invention can be used for preventing or treating pain by administration after a surgical operation by a general method commonly used in medicine.
- a surgical operation by a general method commonly used in medicine.
- various types of surgery that can be used in combination with the compounds of the present invention, and in particular, scar resection, nerve cryocoagulation, peripheral nerve resection, spinal dorsal root excision, sympathetic nerve resection, spinal dorsal root approach tract destruction, cord tomy, frontal lobe resection preferable.
- the compound of the present invention can also be applied to the prevention or treatment of inflammatory bowel syndrome and the like.
- the production method of the compound of the present invention represented by the general formula [1] will be specifically described, but the present invention is of course not limited to these production methods.
- the compound of the present invention may be synthesized according to the following production method A or B, but may also be produced according to the following examples or referring to these production methods.
- the reaction sequence can be appropriately changed.
- the reaction may be performed from a process or a substitution site that seems to be rational.
- compound (X) may be introduced prior to the introduction of compound (I I), or vice versa.
- the formation of the 3,4-dihydrobenzoxazine ring may be subjected to a ring-closing reaction to form the heterocycle before introducing the compound (II) and / or the compound (X).
- a ring-closing reaction may be carried out to form the heterocycle. If there is a reactive functional group, it may be protected or deprotected appropriately. In order to promote the progress of the reaction, a reagent other than the exemplified reagents can be appropriately used.
- the following production process flow is an example of a typical production method, but the production of the compound of the present invention is not particularly limited to the following method. All the compounds obtained in each step can be isolated and purified by a conventional method, but in some cases, the next step can be proceeded without isolation and purification.
- R is a carboxy protecting group (where carboxy protecting group means a carboxy protecting group commonly used in the field of organic synthetic chemistry, such as methyl, ethyl, propyl, tert — Butyl group, benzyl group, paramethoxybenzyl group, etc.) and represents an ester that is easily led to carboxylic acid by hydrolysis or catalytic hydrogenation reaction.
- carboxy protecting group means a carboxy protecting group commonly used in the field of organic synthetic chemistry, such as methyl, ethyl, propyl, tert — Butyl group, benzyl group, paramethoxybenzyl group, etc.
- a nitrogen atom such as a black mouth, bromo, etc., or a three-two-headed benzene senorephonyloxy group, p — ⁇ norens norehoninole xy group, a benzene senorephoninoreoxy group, p —Snorephoni such as bromobenzenes / rephoninoreoxy group, methanesolephoninoreoxy group or trifanolorethans / reoxy group .
- Represents a Reokishi radical R ' is a protecting group of the phenolic hydroxyl group easily removable by hydrolysis or catalytic hydrogenation reaction (where full - Nord hydroxyl group
- the protecting group means a phenolic hydroxyl protecting group generally used in the field of synthetic organic chemistry.
- R "is a hydroxyl-protecting group that can be easily removed by hydrolysis or catalytic hydrogenation (wherein the hydroxyl-protecting group means a hydroxyl-protecting group generally used in the field of synthetic organic chemistry, for example, A methoxymethyl group, a methoxyethyl group, a benzyl group, a tetrahydro-biranyl group, a acetyl group, etc.) Other symbols are as defined above.
- compound (I I I) is obtained from compound (I) and compound (I I) by a palladium-catalyzed Buchwa a 1d / Hartwig type amination reaction.
- the compound (I) is mixed with palladium acetate and 2,2'-bis (diphenylphosphino) in toluene, 1,4-dioxane, tetrahydrofuran, etc. or a mixed solvent thereof.
- an acid such as hydrochloric acid or trifluoroacetic acid in a combined solvent at o ° c to reflux temperature, preferably 0 ° C to 50 ° C, for 0.5 to 24 hours, preferably 0.5 to 8 hours.
- R ′ is a benzyl group or the like
- R ′ is a benzyl group or the like
- Compound (IV) can be obtained by reacting at a temperature of from ° C to reflux temperature, preferably from about 20 ° C to 50 ° C, for 0.5 to 96 hours, preferably 1 to 48 hours. it can. 3rd process
- compound (IV) is reacted with compound (V) under basic conditions to obtain compound (VI).
- Compound (VI) can be obtained by reacting at 0 ° C to reflux temperature, preferably 0 ° C to 60 ° C, for 0.5 to 24 hours in the presence of a base such as um or tritylamine. . 4th process
- the compound (VI) is mixed with carbonic acid form, tetrahydrofuran, N, N-dimethylformamide, .N, N-dimethylacetamide, dimethylsulfoxide, ethyl acetate, or a mixed solvent thereof.
- a base such as sodium, potassium carbonate, sodium hydroxide, lithium hydroxide, triethylamine, etc., 0 ° C to reflux temperature, preferably 0 ° C to 60 ° C, 0.5
- Compound (VII) can be obtained by reacting for 24 hours to 24 hours.
- compound (V I I I) is obtained by removing R from compound (V I I).
- compound (VII) when R is a methyl group, an ethyl group, a propyl group, etc., compound (VII) is mixed with water, methanol, ethanol, propanol, tetrahydrofuran, or a mixed solvent thereof, sodium hydroxide, water Using a base such as oxidizing power lithium, lithium hydroxide, carbonic acid lithium, sodium carbonate, etc. at 120 ° C to reflux temperature, preferably 20 ° C to reflux temperature for 0.5 hours to Compound (VIII) can be obtained by hydrolysis for 24 hours, preferably 0.5 to 8 hours.
- a base such as oxidizing power lithium, lithium hydroxide, carbonic acid lithium, sodium carbonate, etc.
- the compound (VII) when R is a tert-butyl group, the compound (VII) is insoluble in solvent, water, methanol, ethanol, propanol, tetrahydrofuran, etc., or a mixed solvent thereof such as hydrochloric acid, trifluoroacetic acid, etc.
- Compound (VIII) by reacting with acid at 0 ° C to reflux temperature, preferably 0 ° C to 50 ° C, for 0.5 to 24 hours, preferably 0.5 to 8 hours. Can be obtained.
- Step 6 in methanol, ethanol, propanol ⁇ /, tetrahydrofuran, etc., or a mixed solvent thereof, in the presence of a palladium carbon catalyst, etc., using hydrogen or ammonium formate at about o ° c to reflux temperature, preferably Can be obtained by reacting at about 20 ° C. to 50 ° C. for 0.5 hours to 96 hours, preferably 1 hour to 48 hours.
- compound (VIII) when R ′′ is a acetyl group, compound (VIII) can be converted to pyridine, triethyl with acetyl chloride or acetic anhydride in the presence of chlorophenol, tetrahydrofuran, toluene, ethyl acetate, pyridine or no solvent.
- O ° c to reflux temperature preferably 0 ° C to 50 ° C, 0.5 to 24 hours, preferably 0.5 hours in the presence or absence of a base such as lumine.
- Compound (IX) can be obtained by reacting for 8 hours.
- compound (VIII) When R “is a tetrahydrodropirael group, compound (VIII) can be converted to 2,3-dihydropyran with p-toluenesulfonic acid, hydrogen chloride, etc. in the presence of chloroform, tetrahydrofuran, toluene, ethyl acetate or no solvent.
- Compound is obtained by reacting in the presence of a catalyst at 0 ° C to reflux temperature, preferably 0 ° C to 50 ° C, for 0.5 to 24 hours, preferably 0.5 to 8 hours.
- (IX) can be obtained.
- R " is a methoxymethyl group, a methoxyethoxymethyl group, or a benzyl group
- the compound (VIII) is dissolved in a solvent such as tetrahydrofuran, N, N-dimethylformamide, sodium hydride, lithium diisopropylamide, etc.
- a solvent such as tetrahydrofuran, N, N-dimethylformamide, sodium hydride, lithium diisopropylamide, etc.
- methoxymethyl chloride, methoxy methoxymethyl chloride, benzyl chloride or benzyl chloride is at 0 ° C to the reflux temperature, preferably 0 ° C to 50 ° C, and 0.
- Compound (IX) can be obtained by reacting for 5 to 24 hours, preferably 0.5 to 8 hours.
- compound (X I) is obtained by a condensation reaction between compound (I X) and compound (X).
- compound (IX) when a condensation reaction is carried out using a condensing agent, compound (IX) is mixed with N, N-dimethylformamide, methylene chloride, black mouth form or the like in a mixed solvent thereof.
- Compound (X) with a condensing agent such as mid, 1-ethyl-3- (3-dimethylaminopropyl) monocarbodiimide and 120 ° C to reflux temperature, preferably about 0 ° C to Compound (XI) can be obtained by reacting at 50 ° C. for 1 hour to 48 hours, preferably about 1 hour to 24 hours.
- additives such as hydroxybenzotriazole and N-hydroxysuccinic acid imide may be added.
- compound (IX) When the condensation reaction is carried out via an acid chloride, compound (IX) is dissolved in chloroform, methylene chloride, tetrahydrofuran, etc. or a mixed solution thereof.
- (IX) acid chloride is obtained by reacting with thioylucide, oxalyl chloride, etc. in a medium, and this is added with toluene, blackform, tetrahydrofuran, etc. or a mixed solvent thereof, triethylamine, In the presence of a base such as pyridine, compound (X) and 120 ° C to reflux temperature, preferably about 0 ° C to 40 ° C, 0.5 hours to 24 hours, preferably 0.5 hours. Compound (XI) can be obtained by reacting for 12 to 12 hours. 8th process
- R " is a acetyl group
- compound (XI) is mixed with tetrahydrofuran, ethanol, methanol, isopropanol, water, or a mixed solvent thereof, lithium hydroxide, sodium hydroxide, lithium hydroxide, carbonic acid carbonate. 120 ° C to reflux temperature, preferably about 0 ° C to 40 ° C, 0.5 hours to 24 hours, preferably 0.5 hours to 12 hours
- a compound represented by the general formula [1] can be obtained.
- R " is a methoxymethyl group, a methoxymethyl group, a tetrahydrobiranyl group, or a acetyl group
- the compound (XI) can be removed without solvent or with water, methanol, ethanol, propanol, tetrahydrofuran, or a mixed solvent thereof.
- Medium, acid such as hydrochloric acid, trifluoroacetic acid, etc. at 0 ° C to reflux temperature, preferably 0 ° C to 50 ° C, 0.5 hours to 24 hours, preferably 0.5 hours to By reacting for 8 hours, a compound represented by the general formula [1] can be obtained.
- R " is a benzyl group, etc.
- compound (XI) is replaced with hydrogen, ammonium formate, etc. in the presence of a palladium carbon catalyst in methanol, ethanol, propanol, tetrahydrofuran, etc. or a mixed solvent thereof.
- a palladium carbon catalyst in methanol, ethanol, propanol, tetrahydrofuran, etc. or a mixed solvent thereof.
- Compound (VIII) is mixed with N, N-dimethylformamide, methyl chloride, chloroform, etc., or a mixed solvent thereof, dichlorohexanocarbodiimide, 1-ethyl _ 3— (3 —Dimethylaminopropyl) Compound (X) with a condensing agent such as rubodiimide, and —20 ° C. to reflux temperature, preferably about 0 ° C. to 50 ° C., 1 hour to 48 hours
- the compound of the present invention represented by the general formula [1] can be obtained by reacting preferably for about 1 to 24 hours. In this case, additives such as hydroxybenzotriazole and N-hydroxysuccinic acid imide may be added.
- the salt of the compound of the present invention represented by the general formula [1] can be produced according to a conventional method, for example, as follows.
- the compound of the present invention represented by the general formula [1] is mixed with a solvent (for example, water, methanol, ethanol, isopropenoleanol, acetone, 2-butanone, tetrahydrofuran, ethyl acetate, isobutyl acetate, jetyl).
- a solvent for example, water, methanol, ethanol, isopropenoleanol, acetone, 2-butanone, tetrahydrofuran, ethyl acetate, isobutyl acetate, jetyl.
- Tetrahydrofuran (3 mL) was stirred under ice-cooling with triethylamine (0.19 1 mL), ketyl carbonate (0.13 1 mL), and then obtained in the previous step (S) — 4 — (5 — Picolin _ 2 — Yil)
- S Picolin _ 2 — Yil
- One 3 Hydroxyme Tilu N— [3,5-Difluoro-4- (1-carboxy 1-methyl) ethyloxyphenyl] 1 3,4-dihydr draw 2 H-Benzo [1, 4] oxazine 1 8-carboxamide (5 86 mg) of Tetrahydrofuran suspension (5.9 mL) was added and stirred for 1 hour at room temperature.
- Test example [1 1 Inhibition of intracellular Ca2 + influx
- V R 1 activity was evaluated by measuring intracellular Ca2 + uptake.
- MES morpholinoethanesulfonic acid
- a 10 mM DMSO solution of the test substance was diluted to a concentration of 25 M with Hank sbuffer (pH 6.5) to give a test substance solution.
- the membrane permeability coefficient (P a p p) was calculated from the following formula.
- test substance was dissolved in a mixed solution of CH 3 CN and JP 1 liquid (volume ratio 3: 7) and adjusted to 0.05 mM in a HPLC vial.
- the test substances were measured by HPLC after 0 and 8 hours at 40 ° C. The measured value at 0 hour was set to 100%, and the residual rate of the test substance after 8 hours was determined.
- “Japan 1st liquid” means a solution prepared by adding 21 ml of concentrated hydrochloric acid to 6 g of sodium chloride and adjusting to 3 L with distilled water. Inhibition of Ca2 + influx into cells (Test Example [1]), Metabolic Stability Test in Liver S9 (Test Example [2]) and In Vitro Membrane Permeability Test (Test Example [3]) The results for are shown in Tables 4 to 6 below.
- the values are as shown in Tables 4-6, 0.0 2 4 nM, 0.0 3 8 nM, 0.24 4 nM, 0.0 1 9 nM, 0.66 nM, 0.15 nM, respectively. 0.14 nM, 0.03 8 nM, 0.54 nM, 0.69 nM, the average IC 5 of these 10 compounds.
- the value is 0.2 5 n M, 7 eyes.
- Example 1 - 1, 1 one 2, 1 one 4 and IC 5 0 values of the compounds 1 _ 8 are each 0.0 2 4, 0.0 3 8, 0.0 1 9, 0.0 3 8 had excellent VR 1 activity inhibition.
- the IC 5 () values of the compounds of Comparative Examples 1 to 1 3 are shown in Tables 4 to 6, and are 3 nM, 1.3 nM, 18 nM, 5.2 nM, 4 2.0 nM, respectively. , 0.3 nM, 0.4 nM, 7 nM, 0.1 2 nM, 0.0 4 nM, 0.36 nM, 0.0 3 nM, 0.1 2 nM, and these 1 3 Average IC 5 of individual comparative compounds. The value was 5.99 9 nM.
- the compound of the present invention averaged IC 5 compared to the comparative compound. It had an inhibitory activity of about 24 times by value.
- the residual ratio of human liver S 9 in the compounds of Examples 1 to 1 to 1 to 10 included in the compound of the present invention represented by the general formula [1] is as shown in Tables 4 to 6. 90.8%, 65.3%, 59.6%, 39.7%, 82.2%, 91.8%, 50.4%, 91.5%, 7 7.3% and 92.2%, and the average survival rate of human liver S9 for these 10 compounds was 74%.
- the residual rates of the compounds of Examples 1 1 1 1 1 6 1-8 and 1 1 1 1 0 are not less than 90%, and a significantly higher residual rate, ie, a significantly higher liver S 9 It showed metabolic stability. Therefore, these compounds will be useful as drugs that are remarkably superior in that they are not susceptible to oxidative metabolism and will have sustained action.
- the invitro membrane permeability of the compounds of the present invention represented by the general formula [1] is shown in Tables 4 to 6 as follows. / sec.) 8. 5 9 x 1 0— H , 2 0. 9 6 xl 0— 6 , 2 6. 9 3 xl 0— 6 , 3 0. 2 5 x 1 0— 6 , 3 8. 0 7 xl 0 - 6, 3 7. 5 3 xl 0- 6, 3 7. 9 4 xl 0 _ 6, 1 3. 6 1 ⁇ 1 0- 6, 5 0. 3 6 xl 0- 6, 3 9 . a 2 2 xl 0 _ 6, these 1 average P app values of zero or the compound (c mZ sec.) was 3 0. 3 5 x 1 0- 6 .
- the membrane permeability of the compound of Example 1 1 2 to 1 1 1 0 is 1 0 x 1 0
- Comparative Examples 1 to 1 3 of the I ⁇ matter P APPI straight (cm / sec.), As shown in Table 4-6, respectively 2 7. 1 ⁇ 1 0- 6, 2 4. 2 x 1 0- 6, 2 5. 6 x 1 0 one 6, 5. 3 x 1 0- 6 , 7. 9 x 1 0- 6, 2 1. I xl 0- fi, 1 8. 2 xl 0- 6, 4 3. 1 x 1 0- 6, 1 9. 4 x 1 0 "6, 6. 7 xl 0 _ 6, 4 0. 3 xl 0 _ 6, 1 0. 4 x 1 0 one 6, 2 8. a 6 xl O-6, the average P app values of 1 3 and the comparative compound (c / sec.) was 2 1. 3 8 x 1 0- 6.
- the compound of the present invention had a membrane permeability about 1.4 times that of the average P ap P value compared to the comparative compound.
- JP 1 liquid is assumed to have a pH equivalent to that of gastric acid, it is generally known that the stability in it suggests stability in gastric juice. Therefore, these compounds will be useful as excellent medicaments in that they are more stable in gastric juice than Comparative Compound 13.
- BCTC which is known as a substance that inhibits VR 1 activity, has several inhibitory activities (IC 50 values) according to the literature (J Pharmacol Exp Ther. 2003 Jul; 306 (1): 377-86). It is known to be nM. Also in the tests we conducted, BCTC IC 5. We have confirmed that the value is a few nM.
- Metabolic stability is one of the important requirements for pharmaceutical products, and those having metabolic stability of 80% or more are preferable.
- Examples 1 — 1, 1 — 6,. 1 — 8 and 1 1 and 10 have a residual rate of 90% or more, and a significantly higher residual rate, ie, a significantly higher liver S 9 It showed metabolic stability.
- Comparative Compounds 1, 2, 3, 4, 10, 13, etc. also showed excellent metabolic stability, but Comparative Compounds 1, 2, 3, and 4 had IC 5 .
- the value was 1 nM or more, which was not satisfactory in terms of inhibitory activity.
- comparative compound 1 0 were not satisfactory in terms of a and membrane permeable P app values 6. 7 x 1 0 _ 6.
- Comparative Compound 13 was poor in stability in gastric juice and was not always satisfactory.
- the membrane permeability, as the present invention compound of the above had approximately one.
- Examples 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 9, 1 to 1 0 have a P app value of 3 0 X 1 0— H or higher membrane permeability. It was.
- Comparative Example 8 had high membrane permeability, but the Comparative Example 8 compound had an inhibitory activity IC 5 .
- the value is 7 nM, which is not satisfactory in terms of inhibitory activity.
- Comparative Example 1 1 Compound also has a residual ratio of human liver S9, which is an indicator of metabolic stability, of 66.7%. It was not always satisfactory as a medicine.
- Comparing the compound of Comparative Example 1 3 and the compound of Example 1 1 1 differs in that the former has only one fluorine atom of the phenyl group, whereas the latter has two fluorine atoms.
- the latter is IC 5 compared to the former.
- the value has risen by a factor of about 5, which is a surprising result that could not be expected by those skilled in the art.
- the compounds represented by the general formula [1], particularly the compounds of Examples 1 1 to 1 1 1 10 have excellent VR 1 inhibitory activity and excellent metabolic stability in liver S 9 and Z or It is a compound that combines high membrane permeability.
- Example 1 1 to 1_10 contained in the compound represented by the general formula [1] are markedly superior in terms of effectiveness as VR 1 activity inhibitors. It is not only useful as a drug, but it is not easily oxidatively metabolized, has a long-lasting effect, and has a high absorbability. Will be useful.
- these compounds are not only useful as drugs that are remarkably superior in terms of their effectiveness as VR 1 activity inhibitors, but they are not susceptible to oxidative metabolism and have a sustained action. It is expected to be put to practical use as a remarkably excellent medicine in that it will have high absorbability.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006330278A AU2006330278A1 (en) | 2005-12-28 | 2006-12-22 | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (VR1) activity |
CA002632508A CA2632508A1 (en) | 2005-12-28 | 2006-12-22 | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
BRPI0620757-0A BRPI0620757A2 (pt) | 2005-12-28 | 2006-12-22 | compostos de 3,4-dihidrobenzoxazina, composições farmaucêuticas, inibidores da atividade do receptor de vanilóide subtipo 1(vr1), pacote comercial, e usos dos referidos compostos |
JP2007552030A JP4086895B2 (ja) | 2005-12-28 | 2006-12-22 | 3,4−ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
EP06843688A EP1967519B1 (en) | 2005-12-28 | 2006-12-22 | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
IL191560A IL191560A0 (en) | 2005-12-28 | 2008-05-20 | 3,4-dihydrobenzoxazine derivatives and pharmaceutical compositions containing the same |
NO20083103A NO20083103L (no) | 2005-12-28 | 2008-07-10 | 3,4-Dihydrobenzoksazinforbindelse og inhibitor av vanilloidreseptor type 1-(VR1)-aktivitet |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-377754 | 2005-12-28 | ||
JP2005377754 | 2005-12-28 | ||
US75629606P | 2006-01-05 | 2006-01-05 | |
US60/756,296 | 2006-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007074916A1 true WO2007074916A1 (ja) | 2007-07-05 |
Family
ID=38218135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/326314 WO2007074916A1 (ja) | 2005-12-28 | 2006-12-22 | 3,4-ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1967519B1 (ja) |
JP (1) | JP4086895B2 (ja) |
KR (1) | KR20080080155A (ja) |
AU (1) | AU2006330278A1 (ja) |
CA (1) | CA2632508A1 (ja) |
IL (1) | IL191560A0 (ja) |
NO (1) | NO20083103L (ja) |
RU (1) | RU2427579C2 (ja) |
WO (1) | WO2007074916A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009010529A1 (en) * | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
JP2011518152A (ja) * | 2008-04-18 | 2011-06-23 | テウン ファーマシューティカル カンパニー,リミテッド | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006019A1 (fr) | 2001-07-10 | 2003-01-23 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicinale destinee au traitement de la cystite interstitielle |
WO2003053945A2 (en) | 2001-12-20 | 2003-07-03 | Smithkline Beecham P.L.C. | Urea derivatives and their use as vanilloid receptor antagonists |
JP2003192673A (ja) | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
WO2003068749A1 (en) | 2002-02-15 | 2003-08-21 | Glaxo Group Limited | Vanilloid receptor modulators |
WO2003080578A1 (en) | 2002-03-22 | 2003-10-02 | Merck Sharp & Dohme Limited | Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain |
WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
JP2004506714A (ja) | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
WO2005023807A2 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
JP2005518371A (ja) * | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
WO2005077938A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005077944A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain |
WO2005103018A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Urea derivatives as antagonists of the vanilloid receptor (vr1) |
WO2006006741A1 (ja) | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | 縮合ベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
-
2006
- 2006-12-22 EP EP06843688A patent/EP1967519B1/en active Active
- 2006-12-22 CA CA002632508A patent/CA2632508A1/en not_active Abandoned
- 2006-12-22 KR KR1020087015678A patent/KR20080080155A/ko not_active Application Discontinuation
- 2006-12-22 JP JP2007552030A patent/JP4086895B2/ja not_active Expired - Fee Related
- 2006-12-22 WO PCT/JP2006/326314 patent/WO2007074916A1/ja active Application Filing
- 2006-12-22 RU RU2008130895/04A patent/RU2427579C2/ru not_active IP Right Cessation
- 2006-12-22 AU AU2006330278A patent/AU2006330278A1/en not_active Abandoned
-
2008
- 2008-05-20 IL IL191560A patent/IL191560A0/en unknown
- 2008-07-10 NO NO20083103A patent/NO20083103L/no not_active Application Discontinuation
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506714A (ja) | 2000-08-21 | 2004-03-04 | パシフィック コーポレーション | 新規チオ尿素化合物及びこれを含有する薬学的組成物 |
WO2003006019A1 (fr) | 2001-07-10 | 2003-01-23 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicinale destinee au traitement de la cystite interstitielle |
JP2005518371A (ja) * | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
JP2005516951A (ja) * | 2001-12-20 | 2005-06-09 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 尿素誘導体およびバニロイド受容体アンタゴニストとしてのその使用 |
WO2003053945A2 (en) | 2001-12-20 | 2003-07-03 | Smithkline Beecham P.L.C. | Urea derivatives and their use as vanilloid receptor antagonists |
JP2003192673A (ja) | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
WO2003068749A1 (en) | 2002-02-15 | 2003-08-21 | Glaxo Group Limited | Vanilloid receptor modulators |
WO2003080578A1 (en) | 2002-03-22 | 2003-10-02 | Merck Sharp & Dohme Limited | Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain |
WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
WO2005023807A2 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
WO2005077938A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005077944A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain |
WO2005103018A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Urea derivatives as antagonists of the vanilloid receptor (vr1) |
WO2006006741A1 (ja) | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | 縮合ベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
Non-Patent Citations (18)
Title |
---|
BEVAN S; GEPPETTI P., TRENDS NEUROSCI., vol. 17, 1994, pages 509 - 512 |
CARLTON SM; COGGESHALL RE., NEUROSCI. LETT., vol. 310, 2001, pages 53 - 56 |
CATERINA MJ ET AL., NATURE, vol. 389, 1997, pages 816 - 824 |
CATERINA MJ ET AL., SCIENCE, vol. 288, 2000, pages 306 - 313 |
CHUANG HH ET AL., NATURE, vol. 411, 2001, pages 957 - 962 |
DAVIS LB; GRAY J; GUNTHORPE MJ ET AL., NATURE, vol. 405, 2000, pages 183 - 187 |
IKEDA Y ET AL., LIFE SCIENCE, vol. 69, 2001, pages 2911 - 2919 |
J PHARMACOL EXP THER., vol. 306, no. 1, July 2003 (2003-07-01), pages 377 - 86 |
NAT. NEUROSCI., vol. 5, 2002, pages 856 - 860 |
NUMAZAKI M; TOMINAGA M, BIOCHEMISTRY, vol. 75, 2003, pages 359 - 371 |
PREMKUMAR LS; AGARWAL S; STEFFEN D., J. PHYSIOL., vol. 545, 2002, pages 107 - 117 |
See also references of EP1967519A4 |
SHU X; MENDELL LM., NEUROSCI. LETT., vol. 274, 1999, pages 159 - 162 |
SUGIURA T ET AL., J. NEUROPHYSIOL., vol. 88, 2002, pages 544 - 548 |
SZALLASI A; BLUMBERG PM., PHARMACOL. REV., vol. 51, 1999, pages 159 - 212 |
TOMINAGA M; WADA M; MASU M., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 6951 - 6956 |
YANG D; GEREAU RW 4TH., J. NEUROSCI., vol. 22, 2002, pages 6388 - 6393 |
YIANGOU Y ET AL., LANCET, vol. 357, 2001, pages 1338 - 1339 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009010529A1 (en) * | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
US8618120B2 (en) | 2007-07-18 | 2013-12-31 | Novartis Ag | Synergistic combinations of VR-1 antagonists and COX-2 inhibitors |
JP2011518152A (ja) * | 2008-04-18 | 2011-06-23 | テウン ファーマシューティカル カンパニー,リミテッド | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 |
Also Published As
Publication number | Publication date |
---|---|
EP1967519A1 (en) | 2008-09-10 |
RU2427579C2 (ru) | 2011-08-27 |
KR20080080155A (ko) | 2008-09-02 |
AU2006330278A1 (en) | 2007-07-05 |
NO20083103L (no) | 2008-09-29 |
EP1967519A4 (en) | 2010-08-04 |
CA2632508A1 (en) | 2008-06-05 |
IL191560A0 (en) | 2008-12-29 |
JP4086895B2 (ja) | 2008-05-14 |
RU2008130895A (ru) | 2010-02-10 |
EP1967519B1 (en) | 2012-09-05 |
JPWO2007074916A1 (ja) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4018739B2 (ja) | 縮合ベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 | |
US7906508B2 (en) | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity | |
JP6043290B2 (ja) | 縮合複素環化合物 | |
ES2350959T3 (es) | Moduladores de bencimidazol de vr1. | |
EP3638235A1 (en) | Compounds for modulating s1p1 activity and methods of using the same | |
US20100022523A1 (en) | 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors | |
CN101213174A (zh) | 羟吲哚化合物及其作为治疗剂的用途 | |
JPWO2005079845A1 (ja) | 片頭痛予防薬 | |
ES2533310T3 (es) | Derivado de triazol para uso en el tratamiento del dolor neuropático y de la fibromialgia | |
WO2007074916A1 (ja) | 3,4-ジヒドロベンゾオキサジン化合物及びバニロイド受容体1型(vr1)活性阻害剤 | |
TW201718548A (zh) | 哌嗪(piperazine)衍生物 | |
CN115427410B (zh) | 酰胺或者磺酰胺类衍生物及其应用 | |
JP4789289B2 (ja) | 3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 | |
JPH11512710A (ja) | アルファ1bアドレナリンレセプターアンタゴニスト | |
MX2008008622A (es) | Compuestos 3,4-dihidrobenzoxazina e inhibidores de la actividad del receptor vanilloide subtipo 1 (vr1). | |
TW200529820A (en) | Chroman derivatives | |
JP2019509321A (ja) | 疼痛を処置するための組み合わせ | |
BRPI0620757A2 (pt) | compostos de 3,4-dihidrobenzoxazina, composições farmaucêuticas, inibidores da atividade do receptor de vanilóide subtipo 1(vr1), pacote comercial, e usos dos referidos compostos | |
CA2628476C (en) | Pharmaceutical for use in the treatment of ureterolithiasis | |
WO2017073710A1 (ja) | モルヒナン誘導体及びその医薬用途 | |
BR112017023818B1 (pt) | Composto, e, medicamento | |
MX2008006694A (en) | Pharmaceutical for use in the treatment of ureterolithiasis | |
JPWO2013058361A1 (ja) | アンドロゲン受容体拮抗化合物の結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680050068.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007552030 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006843688 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191560 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501240 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2008000349 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2632508 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006330278 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008061097 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08066405 Country of ref document: CO Ref document number: 3311/CHENP/2008 Country of ref document: IN Ref document number: 1020087015678 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569468 Country of ref document: NZ Ref document number: MX/A/2008/008622 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006330278 Country of ref document: AU Date of ref document: 20061222 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008130895 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0620757 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |